Why is BNGO stock up?
On one hand, it has big potential with its Saphyr optical genome mapping instrument. That's why, as a result of a spate of positive developments, shares skyrocketed in value around the start of 2021. On the other hand, something else may or may not have played a role in the nearly twenty-fold run-up in BNGO shares.Oct 28, 2021
Is BNGO expected to rise?
Bionano Genomics Inc (NASDAQ:BNGO) The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +278.79% increase from the last price of 1.98.
Is BNGO a good investment?
Based on his analysis, DeGeeter rates BNGO stock as “outperform” with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.Dec 14, 2021
Is BNGO a buy or sell?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Who owns BioNano genomics?
The Vanguard Group, Inc.
How much will BNGO be worth?
Bionano Genomics net worth as of April 13, 2022 is $0.62B. BioNano Genomics, Inc.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.May 7, 2021
Does ARKG hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Is BNGO undervalued?
Bionano (BNGO) Stock May Still Be Undervalued by Over 100%, Analyst Says.Aug 25, 2020
What type of stock is BNGO?
Common Stock (BNGO)
What does BNGO company do?
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.